JWH-x Synthetic Cannabinoids Research Dashboard
Clinical Studies
0
Clinical Meta-analyses
1
Double-blind human trials
1
Clinical human trials
Pre-Clinical Studies
39
Animal studies
22
Laboratory studies
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 105 studies associated with JWH-x Synthetic Cannabinoids.
Here is a small sampling of JWH-x Synthetic Cannabinoids studies by title:
- Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice
- Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?
- Synthetic Cannabinoids Induce Autophagy and Mitochondrial Apoptotic Pathways in Human Glioblastoma Cells Independently of Deficiency in TP53 or PTEN Tumor Suppressors
- The Activation of Cannabinoid Type-2 Receptor with JWH-133 Protects Uterine Ischemia/Reperfusion-Induced Damage
- A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes
Components of the JWH-x Synthetic Cannabinoids Research Dashboard
- Top medical conditions associated with JWH-x Synthetic Cannabinoids
- Proven effects in clinical trials for JWH-x Synthetic Cannabinoids
- Receptors associated with JWH-x Synthetic Cannabinoids
- Individual study details for JWH-x Synthetic Cannabinoids
Ready to become a subscriber? Go to our PRICING page.
Filter Cannabinoid
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Terpenes
- Receptors
- Ligands
- Study Result
- Year of Publication
Overview - JWH-x Synthetic Cannabinoids
Description of JWH-x Synthetic Cannabinoids
These groups of compounds are named after the organic chemist John William Huffman. The JWH series contains a number of similar synthetic cannabinoids some of which have been used to produce "synthetic cannabinoids" such as "Spice", or "K2" which have been implemented in a number of well publicized overdoses and fatalities. The compounds are banned in a number of countries such as China, Australia, or Ireland for example. For example, one of these compounds JWH-018 is relatively easy to produce and available for sale on the internet.
Other Names:
JWH Family Synthetic Cannabinoids
JWH-x Synthetic Cannabinoids Properties and Effects
Analgesia. Adverse effects can include anxiety, agitation, seizure, death
JWH-x Synthetic Cannabinoids Receptor Binding
Strong affinity for CB1 at Ki of 9nM
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.